Carolina Lopez-Rubalcava

Dr. Carolina Lopez-Rubalcava

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2000 in Neuropsychopharmacology
Verified
Journal Article
Closed access
CLCarolina Lopez-Rubalcava
Carolina Lopez-Rubalcava

1 April 2002 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
PRPeter A Rittenhouse
Peter A Rittenhouse
CLCarolina Lopez-Rubalcava
Carolina Lopez-Rubalcava
GSGregg D Stanwood
Gregg D Stanwood
ILIrwin Lucki
Irwin Lucki

22 October 2002 in Neuropsychopharmacology
Verified
Journal Article
Closed access
Erika Estrada CamarenaErika Estrada Camarena
Erika Estrada Camarena
AFAlonso Fernández-Guasti
Alonso Fernández-Guasti
CLCarolina Lopez-Rubalcava
Carolina Lopez-Rubalcava

1 June 2012 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
MMMariano Martínez-Vázquez
Mariano Martínez-Vázquez
RER. Estrada-Reyes
R. Estrada-Reyes
AMA. Martínez-Laurrabaquio
A. Martínez-Laurrabaquio
CLCarolina Lopez-Rubalcava
Carolina Lopez-Rubalcava
GHG. Heinze
G. Heinze

2 September 2011 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
Erika Estrada CamarenaErika Estrada Camarena
Erika Estrada Camarena
CLCarolina Lopez-Rubalcava
Carolina Lopez-Rubalcava
AHAzucena Hernández-Aragón
Azucena Hernández-Aragón
SMSilvia Mejía-Mauries
Silvia Mejía-Mauries
OPOfir Picazo
Ofir Picazo
Controversial results related to effectiveness of estrogen replacement therapy (ERT) to alleviate depression are frequently reported. The discrepancies could be related to (a) time when ERT is initiated after the beginning of menopause and/or (b) type of estrogen used. Furthermore, estrogens modulate the antidepressant effect of different compounds; therefore, the effectiveness of antidepressant drugs could also depend on the menopausal status. The aim of the present study was to analyze whether the time after estrogen decline can influence antidepressant-like effects of two estrogens and/or two antidepressants. Thus, the antidepressant-like actions of 17β-estradiol (E2), 17α-ethynyl-estradiol (EE2), fluoxetine (FLX) and desipramine (DMI) were studied at different periods (1, 3 and 12 weeks) after ovariectomy (OVX), using the forced swimming test (FST). Results showed that OVX increased depressive-like behavior only 1 week after OVX. The antidepressant-like actions of E2, but not those of EE2, were cancelled 12 weeks after OVX. Conversely, antidepressant-like actions of FLX and DMI were observed at 1, 3 and 12 weeks after OVX. In conclusion, while the antidepressant-like effects of estrogens depended on the time at which treatment is initiated after OVX as well as on the estrogenic compound used, antidepressant-like effects of FLX and DMI were not blocked by OVX.

1 January 2006 in Life Sciences
Verified
Journal Article
Closed access
CLCarolina Lopez-Rubalcava
Carolina Lopez-Rubalcava
BPB. Piña-Medina
B. Piña-Medina
RER. Estrada-Reyes
R. Estrada-Reyes
GHG. Heinze
G. Heinze
MMMariano Martínez-Vázquez
Mariano Martínez-Vázquez